1:56 PM
 | 
Apr 06, 2018
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Amyndas reports Phase I data for C3 inhibitor AMY-101

Amyndas Pharmaceuticals S.A. (Glyfada, Greece) reported data from an open-label, U.S. Phase I trial in healthy male volunteers showing that single and multiple ascending doses of...

Read the full 112 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >